Todd Pettingill | Senior Director, Corporate Development & IR |
John Higgins | CEO |
Matt Foehr | COO |
Matt Korenberg | CFO |
Joe Pantginis | H.C. Wainwright |
Matt Hewitt | Craig-Hallum Capital |
Larry Solow | CJS Securities |
Hello, and welcome to the Ligand Pharmaceuticals Second Quarter 2019 Earnings Call. All lines have been placed on mute and today's call is being recorded. At the end of today's presentation, we will have a question-and-answer session. [Operator Instructions].
It is now my pleasure to turn today's program over to Todd Pettingill, Senior Director, Corporate Development and Investor Relations.